Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

• 主要な著者: Weam Othman Elbezanti (著者), Omar S. Al-Odat (著者), Robert Chitren (著者), Jaikee Kumar Singh (著者), Sandeep Kumar Srivastava (著者), Krishne Gowda (著者), Shantu Amin (著者), Gavin P. Robertson (著者), Venkatesh V. Nemmara (著者), Subash C. Jonnalagadda (著者), Tulin Budak-Alpdogan (著者), Manoj K. Pandey (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for myeloma recurrence is the persistent stem cell-like population. It has been demonstrated that overexpression of Bruton's tyrosine kinase (...